ARMH4

Across TCGA pan-cancer cohorts, ARMH4 RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated ARMH4 data layer compared with 7 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ARMH4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ARMH4 expression acts as an unfavorable survival marker, although some lineages such as LAML and SCLC show a favorable association.

MESO, BLCA, and COAD are the cancer types where ARMH4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.421	0.670	<.001	96	view →
BLCA	OS	Tertile	All	0.284	0.545	<.001	74	view →
COAD	DFS	Median	All	0.305	0.616	<.001	67	view →
ACC	DFS	Median	All	0.394	0.750	<.001	57	view →
LAML	DFS	Median	All	0.684	0.454	<.001	48	view →
STAD	OS	Quartile	All	0.442	0.666	<.001	37	view →
SCLC	OS	Quartile	II,III,IV	0.841	0.380	.001	29	view →
LIHC	DFS	Median	III,IV	0.564	0.235	.003	28	view →
KIRC	DFS	Median	II,III,IV	0.858	0.657	.012	26	view →
THCA	OS	Quartile	All	0.971	1.000	.004	26	view →
DLBC	DFS	Median	III,IV	1.000	0.457	.003	24	view →
HNSC	OS	Median	II,III,IV	0.697	0.787	.011	23	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

ARMH4–MESO (OS)

Open the MESO breakdown →